TY - JOUR T1 - Perceptions of partial gland ablation for prostate cancer among men on active surveillance: A qualitative study JF - medRxiv DO - 10.1101/2020.09.15.20195388 SP - 2020.09.15.20195388 AU - Sonia S. Hur AU - Michael Tzeng AU - Eliza Cricco-Lizza AU - Miko Yu AU - Jessica Ancker AU - Erika Abramson AU - Christopher Saigal AU - Ashley Ross AU - Jim C. Hu Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195388.abstract N2 - Objectives Partial gland ablation (PGA) therapy is an emerging treatment modality that targets specific areas of biopsy proven prostate cancer (PCa) to minimize treatment-related morbidity by sparing benign prostate. This qualitative study aims to explore and characterize perceptions and attitudes toward PGA in men with very-low-risk, low-risk, and favorable intermediate-risk PCa on active surveillance (AS).Design 92 men diagnosed with very-low-risk, low-risk, and favorable intermediate-risk PCa on AS were invited to participate in semi-structured telephone interviews on PGA.Setting Single tertiary care center located in New York City.Participants 20 men with very-low-risk, low-risk, and favorable intermediate-risk PCa on AS participated in the interviews.Main outcome measures Emerging themes on perceptions and attitudes toward PGA were developed from transcripts inductively coded and analyzed under standardized methodology.Results Four themes were derived from twenty interviews that represent the primary considerations in treatment decision-making: (1) the feeling of psychological safety associated with low risk disease; (2) preference for minimally invasive treatments; (3) the central role of the physician; (4) and the pursuit of treatment options that align with disease severity. Eleven men (55%) expressed interest in pursuing PGA only if their cancer were to progress, while 9 men (45%) expressed interest at the current moment.Conclusions Though an emerging treatment modality, patients were broadly accepting of PGA for PCa with men primarily debating the risks versus benefits of proactively treating low-risk disease. Additional research on men’s preferences and attitudes toward PGA will further guide counseling and shared decision-making for PGA.What is already known about this subject?Partial gland ablation (PGA) is an emerging treatment option for prostate cancer (PCa) that allows for the targeting of areas of biopsy proven PCa with the goal of minimizing treatment-related morbidity by avoiding treatment of non-cancerous areas of the prostate. We sought to explore patients’ beliefs and attitudes toward partial gland ablation.What are the new findings?We define treatment attributes that are significant to men with localized PCa, and one important theme is of the treatment intensity matching the severity of the disease. PGA appeals to men as middle ground that encompasses the duality of curative treatment and preservation of quality of life.How might these results affect future research or surgical practice?The exploratory themes need further exploration and may be incorporated into shared decision-making discussions in men with low-risk disease, as PGA emerges as a treatment option.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJim Hu is supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Weill Cornell Medicine Institutional Review Board IRB Protocol #: 1703018035All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article. ER -